Novocure Ltd (NVCR)vsNovartis AG ADR (NVS)
NVCR
Novocure Ltd
$15.21
+27.49%
HEALTHCARE · Cap: $1.38B
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 8533% more annual revenue ($56.58B vs $655.35M). NVS leads profitability with a 23.9% profit margin vs -20.8%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVCR
Avoid28
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+83.6%
Fair Value
$64.09
Current Price
$15.21
$48.88 discount
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
ROE of -38.9% — below average capital efficiency
Earnings declined 6.0%
Negative free cash flow — burning cash
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : NVCR
NVCR has a balanced fundamental profile.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : NVCR
The primary concerns for NVCR are Market Cap, Return on Equity, EPS Growth.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Key Dynamics to Monitor
NVCR profiles as a turnaround stock while NVS is a declining play — different risk/reward profiles.
NVCR carries more volatility with a beta of 0.82 — expect wider price swings.
NVCR is growing revenue faster at 8.1% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 28/100), backed by strong 23.9% margins. NVCR offers better value entry with a 83.6% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novocure Ltd
HEALTHCARE · MEDICAL DEVICES · USA
NovoCure Limited, an oncology company, is engaged in the development, manufacture and marketing of Optune for the treatment of a variety of solid tumors. The company is headquartered in Saint Helier, Jersey.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?